Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CASI Pharmaceuticals (CASI) Gross Margin (2022 - 2025)

Historic Gross Margin for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to 49.29%.

  • Pharmaceuticals' Gross Margin fell 26500.0% to 49.29% in Q2 2025 from the same period last year, while for Jun 2025 it was 66.35%, marking a year-over-year increase of 95400.0%. This contributed to the annual value of 39.06% for FY2024, which is 201300.0% down from last year.
  • Pharmaceuticals' Gross Margin amounted to 49.29% in Q2 2025, which was down 26500.0% from 58.0% recorded in Q1 2025.
  • Pharmaceuticals' Gross Margin's 5-year high stood at 107.1% during Q4 2022, with a 5-year trough of 49.29% in Q2 2025.
  • For the 4-year period, Pharmaceuticals' Gross Margin averaged around 61.0%, with its median value being 58.74% (2022).
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -480500bps in 2023, then skyrocketed by 50200bps in 2025.
  • Pharmaceuticals' Gross Margin (Quarter) stood at 107.1% in 2022, then tumbled by -45bps to 59.05% in 2023, then fell by -12bps to 51.95% in 2024, then decreased by -5bps to 49.29% in 2025.
  • Its Gross Margin was 49.29% in Q2 2025, compared to 58.0% in Q1 2025 and 51.95% in Q2 2024.